BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 18, 2026
Home » Authors » Anette Breindl

Anette Breindl

Articles

ARTICLES

BioWorld MedTech’s Oncology Extra for March 31, 2020

March 31, 2020
By Liz Hollis and Anette Breindl
Keeping you up to date on recent developments in oncology, including: How lung tumors seed to brain; UVA looks to genes to improve cancer outcomes; Study shows promise of immunotherapy against solid tumors.
Read More
Acute myeloid leukemia illustration
Gene, meet environment

Setting ‘evolutionary traps’ can lure cancer cells into an ambush

March 30, 2020
By Anette Breindl
As organisms adapt to their environment, adaptations that serve them in their current environment can become liabilities if that environment changes. The control of traits that are an asset in one situation and a liability by the same gene is called antagonistic pleiotropy. In the March 16, 2020, online issue of Nature Genetics, researchers reported a method to systematically identify mutations that conferred antagonistic pleiotropy – in the form of resistance to one drug, but heightened sensitivity to another – in acute myeloid leukemia (AML) cells.
Read More
Leakage in the barrier between the eye and the optic nerve in<br /> glaucoma

Bench Press for March 27, 2020

March 27, 2020
By Anette Breindl
BioWorld looks at translational medicine, including: How the eye cleans itself up; In blood stem cells, selection drives driver mutations early on; Dead cells do tell tales; Selective TGF-beta inhibition helps checkpoint blockade; How lung tumors seed to brain; Butyrate affects regulatory B cells, rheumatoid arthritis; Lamin A/C’s presence in nucleus, absence from membrane both problematic in progeria; Females, males have different metabolic response to intermittent fasting; Ditching PAMs expands CRISPR.
Read More

BioWorld MedTech’s Diagnostics Extra for March 26, 2020

March 26, 2020
By Meg Bryant and Anette Breindl
Keeping you up to date on recent developments in diagnostics, including: Improving TBI prognosis; Speeding detection of antibiotic resistant infections; Multistep method wrests causality from GWAs; In blood stem cells, selection drives driver mutations early on.
Read More
Testing, testing

First repurposing trial for COVID-19 falls flat

March 24, 2020
By Anette Breindl
The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results.
Read More

BioWorld MedTech’s Oncology Extra for March 24, 2020

March 24, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: New study hints that 3D chromatin architecture a key in childhood leukemia; Recruiting NK cells to the antitumor battle; 3D printing meets the medical isotope business.
Read More

BioWorld MedTech’s Neurology Extra for March 20, 2020

March 20, 2020
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: ‘Natural killer’ cells could halt PD progression; Neuroinflammation linked to several forms of dementia; GOF, LOF mutations take different paths to same result; Study links GABA, mitochondria, social defects.
Read More
Person taking medication

Bench Press for March 20, 2020

March 20, 2020
By Anette Breindl
BioWorld looks at translational medicine, including: Heparan sulfate DAMPens acetaminophen toxicity; Study links GABA, mitochondria, social defects; Recruiting NK cells to the antitumor battle; Potassium channel blocker improves motor learning in fetal alcohol syndrome; A20s inflammation-fighting properties decoded; Brown fat activity without fat browning; Agonists selectively wake up melatonin receptor subtypes; Multistep method wrests causality from GWAS; BET on BD1 for cancer, BD2 for inflammation.
Read More

BioWorld MedTech’s Diagnostics Extra for March 19, 2020

March 19, 2020
By Meg Bryant and Anette Breindl
Keeping you up to date on recent developments in diagnostics, including: ‘Virtual peer review’ aids cancer diagnosis; Adding spirometry to lung cancer screenings to detect undiagnosed COPD; See in 3D; AI and sleep medicine.
Read More
Testing, testing

First repurposing trial for COVID-19 falls flat

March 19, 2020
By Anette Breindl
The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results. In 200 hospitalized patients with severe COVID-19, a 14-day regimen of twice-daily treatment with Kaletra/Aluvia (lopinavir/ritonavir, Abbvie Inc.) did not hasten recovery when added to the standard of care.
Read More
View All Articles by Anette Breindl

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing